In the past 12‑18 months the beta lactam beta lactamase inhibitors market has accelerated through a series of strategic moves. In March 2023, Pfizer entered a global partnership with Takeda to co‑develop a next‑generation carbapenem‑protected inhibitor, leveraging Takeda’s enzyme‑profiling platform. The following month, Merck completed its $1.2 billion acquisition of biotech firm AvidBio, gaining access to AvidBio’s novel diazabicyclooctane (DBO) series now in Phase II trials. Early 2024 saw the FDA approve Vabimox, the first oral inhibitor targeting class D OXA‑type enzymes, while the European Medicines Agency released updated guidance on combination therapy labeling, streamlining market entry for dual‑drug products. Meanwhile, venture capital funding surged, with a $150 million Series C round for UK‑based PhageGuard, earmarked for scaling its hybrid phage‑inhibitor platform. These developments, combined with rising hospital demand for carbapenem‑sparing regimens, underscore the dynamic beta lactam beta lactamase inhibitors industry trends that are reshaping antimicrobial stewardship and driving pipeline diversification. In Q2 2024, Sanofi inaugurated a 120,000‑square‑foot manufacturing hub in Singapore, boosting capacity for fixed‑dose combination packs and positioning the company to capture fast‑growing Asia‑Pacific demand.
